You are here: Industry Insights > Roche

News List

Roche taps Lilly executive Garraway as chief medical officer expresspharma
August 21, 2019
Swiss drugmaker Roche Holding named Eli Lilly executive Levi Garraway to succeed Sandra Horning as Chief Medical Officer and head of global product development.
Roche's first FDA-approved tumour-agnostic medicine worldpharmanews
August 19, 2019
Roche announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC).
Roche scores Rozlytrek OK to challenge Bayer—and undercuts it on price fiercepharma
August 18, 2019
Roche’s targeted cancer drug Rozlytrek is officially cleared for U.S. launch—and in not one, but two indications.
Roche gets approval for oncology drug, Rozlytrek biospectrumasia
August 18, 2019
FDA Approves Genentech’s Personalized Medicine for Two Different Indications in ROS1-Positive Non-Small Cell Lung Cancer and NTRK Fusion-Positive Solid Tumors
Roche says Tecentriq prevents disease worsening or death in patients with advanced bladder cancer expresspharma
August 07, 2019
Roche is evaluating treatment in combination with other medicines for early, advanced forms of disease
Could FTC scrutiny of the Roche-Spark merger scuttle future pharma deals? Analysts are fretting fiercepharma
August 04, 2019
When Roche delayed its planned $4.8 billion purchase of gene therapy developer Spark Therapeutics for the fifth time earlier this week, citing the Federal Trade Commission's (FTC's) review of the deal, one burning question emerged among pharma watchers: W
Roche extends $4.3B Spark tender offer yet again. What are watchdogs so worried about? fiercepharma
August 01, 2019
You might have lost count of how many times Roche has extended the tender offer period for shares of Spark Therapeutics. As of Wednesday, it's five. And once again, regulatory delays are part of the problem.
Roche, like Bayer, was hit in Winnti cyberattack fiercepharma
July 28, 2019
It turns out that Bayer was not the only pharma company targeted by the Winnti cyberattack believed to have been instituted by hackers tied to the Chinese government. Roche also was a victim.
Herceptin drops on contracting ahead of U.S. biosim, but Roche sales stomp anyway July 28, 2019
Biosimilars to Roche’s top-selling cancer drugs Herceptin and Avastin entered the U.S. last week. But thanks to PD-L1 inhibitor Tecentriq, hemophilia drug Hemlibra and multiple sclerosis therapy Ocrevus, Roche is still counting on sales growth this year.
Roche confirms cyber-attack from Winnti malware europeanpharmaceuticalreview
July 26, 2019
The pharmaceutical company Roche has affirmed that it was hit by a Winnti cyber-attack, thought to be supported by the Chinese government.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page